**BREATHTEC BIOMEDICAL ATTENDS BC MINISTERS TRADE MISSION TO ISRAEL AND ANNOUNCES APPROVAL OF CLINICAL TRIALS**

**Vancouver, British Columbia, December 19, 2016**[**Breathtec BioMedical, Inc**](http://ctt.marketwire.com/?release=1281367&id=9911236&type=1&url=http%3a%2f%2fbreathtecbiomedical.com%2f).(CSE: [BTH.CN](http://www.marketwired.com/news_room/Stock?ticker=BTH.CN)) (CNSX: [BTH](http://www.marketwired.com/news_room/Stock?ticker=BTH)) (CSE: [BTH](http://www.marketwired.com/news_room/Stock?ticker=BTH)) (OTCQB: [BTHCF](http://www.marketwired.com/news_room/Stock?ticker=BTHCF)) (the “Company” or “Breathtec“), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases is pleased to announce its Lead Engineer, Dr. Raj Attariwala, attended the British Columbia (BC) Ministers Trade Mission to Israel on behalf of Breathtec Biomedical November 13-17, 2016.

BC Finance Minister Michael de Jong led the trade mission to Israel to strengthen intergovernmental relationships, with a focus on the life sciences and cyber security sectors.

During the event, Minister de Jong and members of the delegation met with Israeli government officials, including the nation’s Chief Scientist Avi Hasson and life science stakeholders in Tel Aviv, Jerusalem, Be'er Sheva, and Haifa, as well as Palestinian Authority representatives in the West Bank territory.

The purpose of the mission was to connect BC with some of the top life sciences organizations in Israel and the world, including Technion University in Haifa, the home of three Nobel Laureates, which has been credited worldwide for its ability to generate start-ups and for its significant impacts in clean tech, life sciences, and more.

Those in attendance at the Technion Israel Institute of Technology along with Breathtec’s Dr. Attariwala included BC provincial minister of Finance, the Honourable Michael de Jong, the assistant deputy minister of Health, Heather Davidson, and Technion Vice President for External Relations and Resource Development, Boaz Golany as well as members from Breathtec advisor Professor Hossam Haick's laboratory. At this meeting, Dr. Attariwala announced institutional review board (IRB) ethics approval to initiate Breathtec’s clinical trial of infection detection by breath analysis. This clinical trial will be conducted using the NA-NOSE, an advanced stage, nanotechnology-based breath analysis device from the Technion – Israel Institute of Technology (for more on NA-NOSE, see news release dated Jun 28, 2016).

The institutional review board ethics approval to proceed with a clinical trial of infection detection by breath analysis. is designed to test a minimal risk, point-of-care nanotechnology based device licensed from Technion by Breathtec. The device, if approved, may allow doctors and health professionals to determine if a patient's upper respiratory system is infected with specific bacteria. Canadian patients 6yrs of age and older with potential throat infections are eligible to participate in this upcoming feasibility study which is slated to take place in the greater Vancouver, BC area.

In the controlled laboratory environment, this type of technology has shown that volatile organic compounds (VOC) present in the gas above bacterial cultures can be demonstrated to successfully differentiate between specific types of infectious agents.

Dr. Attariwala states "We look forward to translating this breath-based technology to the clinic from the lab environment, and we hope it can provide health care practitioners a quick and efficient access to diagnostics instead of the customary 3 day wait for swab culture analysis. This delay often results in antibiotic overuse and puts us all at risk from developing antibiotic resistant bacterial strains. We are also pleased with the interest and support that Breathtec has received from BC governmental officials and the Health & Technology District on Innovation Boulevard at Surrey Memorial Hospital.”

For more information, please visit: [www.breathtecbiomedical.com](http://www.breathtecbiomedical.com).

**ON BEHALF OF THE BOARD**

"Kal Malhi"  
President & Director

**For further information, please contact:**

Investor Relations  
Telephone: +1 (352) 327-3152  
Email: [investors@breathtecbiomedical.com](mailto:investors@breathtecbiomedical.com)

*The CSE has neither approved nor disapproved the information contained herein.*

*This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.*

*This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.*

*The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.*